ClinicaliQ Trial Snapshot
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Active Not Recruiting • Phase II • Gastroenterology • NCT05242484.
- Combining two biologic drugs (guselkumab and golimumab) tested for treating ulcerative colitis in patients who haven't responded to other treatments.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy. Conditions: Colitis, Ulcerative Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 577 participants